Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have received a consensus rating of “Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $44.71.

Several research firms have commented on DNTH. Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Wedbush dropped their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Cantor Fitzgerald began coverage on shares of Dianthus Therapeutics in a research note on Thursday, June 27th. They set an “overweight” rating for the company. Finally, Robert W. Baird initiated coverage on Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 price target on the stock.

Dianthus Therapeutics Price Performance

NASDAQ DNTH opened at $25.99 on Wednesday. The firm’s fifty day moving average price is $28.12 and its 200 day moving average price is $26.11. Dianthus Therapeutics has a 12 month low of $6.58 and a 12 month high of $33.77. The company has a market capitalization of $762.81 million, a price-to-earnings ratio of -4.46 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. The firm had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.63 million. As a group, sell-side analysts forecast that Dianthus Therapeutics will post -2.32 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in DNTH. SG Americas Securities LLC acquired a new position in Dianthus Therapeutics during the 2nd quarter worth approximately $112,000. The Manufacturers Life Insurance Company acquired a new position in Dianthus Therapeutics during the second quarter worth $236,000. WINTON GROUP Ltd purchased a new position in Dianthus Therapeutics in the second quarter worth $265,000. Point72 DIFC Ltd acquired a new stake in Dianthus Therapeutics in the second quarter valued at $334,000. Finally, Virtu Financial LLC acquired a new stake in Dianthus Therapeutics in the first quarter valued at $390,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.